Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Standard first-line chemotherapy results in disease progression and death within one year in most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro-oesophageal adenocarcinoma(1–4). Nivolumab plus chemotherapy demonstrated superior overall survival versus chemotherapy at 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Shitara, Kohei, Ajani, Jaffer A., Moehler, Markus, Garrido, Marcelo, Gallardo, Carlos, Shen, Lin, Yamaguchi, Kensei, Wyrwicz, Lucjan, Skoczylas, Tomasz, Bragagnoli, Arinilda Campos, Liu, Tianshu, Tehfe, Mustapha, Elimova, Elena, Bruges, Ricardo, Zander, Thomas, de Azevedo, Sergio, Kowalyszyn, Ruben, Pazo-Cid, Roberto, Schenker, Michael, Cleary, James M., Yanez, Patricio, Feeney, Kynan, Karamouzis, Michalis V., Poulart, Valerie, Lei, Ming, Xiao, Hong, Kondo, Kaoru, Li, Mingshun, Janjigian, Yelena Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967713/
https://www.ncbi.nlm.nih.gov/pubmed/35322232
http://dx.doi.org/10.1038/s41586-022-04508-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967713/
https://www.ncbi.nlm.nih.gov/pubmed/35322232
http://dx.doi.org/10.1038/s41586-022-04508-4

Ejemplares similares